TOFISOPAM: ANXIETY THERAPY IN NEUROLOGIC PROFILE PATIENTS
https://doi.org/10.21518/2079-701X-2016-11-48-50
Abstract
The article deals with the experience of tofisopam application in therapy of anxiety disorders in neurologic profile patients of the rehabilitation inpatient therapy. 45 patients with chronic vertebra-basilar insufficiency, consequences of the ischemic stroke, intervertebral discs lesions and spinal column dorsopathies were examined. The structure of psychic disorders was determined by the presence of the generalized anxiety disorder, organic anxiety disorder, emotionally instable disorder by ICD-10. The physiologic problem characterizing these patients was related to pain and mobility disturbance, general somatic state as well as situations preconditioned by a fact of chronic disease and its psychosocial consequences. The effectiveness of tofisopam is shown with use of psychometric scales CGI, HADS and Spielberg-Khanin Anxiety Scale with respect to reactive anxiety preconditioned by external factors as well as its good tolerability, safety and lack of negative effect on the cognitive sphere. A conclusion about the expediency of tofisopam for rehabilitation of neurologic patients is made, especially patients with vertebra-basilar insufficiency.
About the Authors
I. N. AGAMAMEDOVA
Moscow Scientific and Research Psychiatry Institute – a branch of Serbsky Federal Medical Research Psychiatry and Narcology Center
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
T. E. NIKITINA
Moscow Scientific and Research Psychiatry Institute – a branch of Serbsky Federal Medical Research Psychiatry and Narcology Center
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Грибачева И.А., Жукова Н.Г. Вегетокорригирующее и анксиолитическое действие тофизопама в предклимактерическом периоде. Врач, 2010, 5: 52-57. [Gribacheva I.A., Zhukova N.G. Vegetocorrective and anxiolytic action of tofisopam in pre-climacteric period. Vrach, 2010, 5:52-57].
2. Дюкова Г.М., Саксонова Е.В., Голубев В.Л. Грандак син в неврологической практике (мульти-центровое исследование). Журнал неврологии и психиатрии, 2009, 9: 44-48. [Dyukova G.M., Saxonova E.V., Golubev V.L. Grandaxin in neurologic practice (multi-center study). Zhurnal Nevrologii I Psikhiatrii, 2009, 9: 44-48].
3. Инструкция по медицинскому применению Грандаксина [Электронный ресурс]. Режим доступа: http://medi.ru/doc/a02102. htm>Грандаксин ~ Инструкция (MEDI.RU)./ Patient Information Leaflet for Grandaxin [Electronic Resource]. Access regime: http://medi.ru/doc/a02102.htm>Grandaxin ~ Patient Information Leaflet (MEDI.RU)
4. Кадыков А.С., Манвелов Л.С., Шахпаронова Н.В. Хронические сосудистые заболевания головного мозга (Дисциркуляторная энцефалопатия). М.: ГЭОТАР-Медиа, 2006. 224 с. [Kadykov A.S., Manvelov L.S., Shakhparonova N.V. Chronic vascular brain diseases (Dyscirculatory encephalopathy). M.: GEOTAR-Media, 2006. 224 p].
5. Машковский М.Д. Лекарственные средства. 15 изд., перераб., испр. и доп. М.: «Новая Волна», 2006. 1206 с. [Mashkovsky M.D. Medicinal agents. 15th ed., revised and enlarged. M.: Novaya Volna, 2006, 1206 p].
6. Парфенов В.А. Дисциркуляторная энцефалопатия. М., 2008. 12 с. [Parfenov V.A. Dyscirculatory encephalopathy. M., 2008. 12 p].
7. Ханин Ю.Л. Краткое руководство к применению шкалы реактивной и личностной тревожности Ч.Д. Спилбергера. ЛНИИЕУЛ. Л., 1976. [Khanin Y.L. Short instruction to application of the reactive and personal anxiety scale of C.D. Spielberger].
8. Ярыгин Н.В., Никулин В.В., Лукутина А.И. Опыт применения Грандаксина в коррекции предэкзаменационного стресса у студентов высших учебных заведений. Фарматека, 2005, 108(13): 139-142. [Yarygin N.V., Nikulin V.V., Lukutina A.I. Experience of Grandaxin application in correction of pre-examination stress in students of higher educational institutions. Farmateka, 2005, 108 (13): 139-142].
9. Bernard P, Dufresne-Favetta C, Favetta P, Do Q-T, Himbert F, Zubrzycki S, Scior T. Application of Drug Repositioning Strategy to TOFISOPAM. Current Medicinal Chemistry, 2008, 15: 3196-3203.
10. Goldberg HL, Finnerty RJ. Comparative efficacy of tofisopam and placebo. Am J Psychiatry, 1979, 2(136): 196-199.
11. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976.
12. Horvath EJ, Horvath K, Hamori T, Fekete MIK, Solyom S, Palkovits M. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Progress in Neurobiology, 2000, 60: 309-342.
13. Hovi-Viander M, Kanto J. Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites. Br J Clin Pharmac., 1985, 20: 492-496.
14. Kalashnikov SV, Kalashnikova EA, Kokarovtseva SN. Immunomodulating effects of tofizopam (Grandaxin) and diazepam in vitro. Mediators Inflamm, 2002, 11: 53-59.
15. Pellow S, File SE. Is Tofisopam an Atypical Anxio lytic? Neuroscience Biobehaviora! Reviews, 1986, 10: 221-227.
16. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. ActaPsychiatr. Scand., 1983, 67: 361-370.
Review
For citations:
AGAMAMEDOVA IN, NIKITINA TE. TOFISOPAM: ANXIETY THERAPY IN NEUROLOGIC PROFILE PATIENTS. Meditsinskiy sovet = Medical Council. 2016;(11):48-50. (In Russ.) https://doi.org/10.21518/2079-701X-2016-11-48-50
Views:
1035
Email this article 